...MOS) for all 40 pts was 24.3 months (mo) (range, 4 to 78). MOS of pts achieving CR, PR, and NC were 'not reached", 23.6 ...
...mos with 754 deaths. Median survival time (MST) for both treatment groups was 7.9 mos. Non-P arm was non-inferior to the...
...mos (95% CI, 5.5- 9.2), compared to 7.6 mos (95% CI, 5.2-11.1) for the combination arm (P=NS). Median OS times were not ...
...mos; 1 yr OS 53%, 2 yr OS 18%. 13 completed 6 cycles and went onto maintenance therapy with C225 alone. Respective MS fo...
...mos vs 5 mos [P<0.000001]). The most common grade 3/4 treatment-related AEs for the sunitinib group are hypertension (12...
...mos of treatment (TIA, AMI) Pryidoxine did not ameliorate HFS. Only 4/48 pts stopped therapy due to toxicities. MTD was ...
...mos versus 6.6 mos for the P arm (P=0.0002). Grade 3 or 4 events occurred in ≤5% of pts on Th. Most common grade 2 toxic...
...mos for pts who did or did not have PSA-P by 3 mos.,PSA-P defined as an increase of ≥ 25% over baseline or nadir with an...
...mos vs. 10.1 mos for vinorelbine + C (P=.04). This open-label three-arm trial was designed to assess PCb ± ENZ versus a ...
...mos.), median progression-free survival (PFS) and overall survival (OS) remain at 4/3 and 13/13 months, for treatment-na...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
